Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug […]
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to […]
Allot Announces the Appointment of Eyal Harari as Chief Executive Officer
Hod Hasharon, Israel, May 06, 2024 (GLOBE NEWSWIRE) — Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of […]
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with […]
N2OFF: Save Foods to Target California’s Hemp Market
More than half of US hemp flower grown in California recently received Pre-Harvest Regulatory Approval in California allowing Save Foods […]
Skyward Specialty Announces Secondary Offering of Its Common Stock
HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a […]
Stellantis Pro One Achieves No. 1 Spot in Middle East & Africa Region and Strengthens Commercial Vehicle Leadership in Europe and South America
Stellantis Pro One Achieves No. 1 Spot in Middle East & Africa Region and Strengthens Commercial Vehicle Leadership in Europe […]
AMG Reports Financial and Operating Results for the First Quarter of 2024
Company reports EPS of $4.14, Economic EPS of $5.37 in first quarter Net Income (controlling interest) of $150 million, Economic […]
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 […]
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to […]
